e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
Immunodepression and severe pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulmonary infections in patients receiving treatment of tumor necrosis factor alpha antagonists
Yavuz Havlucu (Manisa, Turkey), Yavuz Havlucu, Fikret Kurhan, Timur Pirildar, Tugba Goktalay, Aysin Sakar Coskun, Pinar Celik, Arzu Yorgancioglu
Source:
International Congress 2015 – Immunodepression and severe pneumonia
Session:
Immunodepression and severe pneumonia
Session type:
Thematic Poster Session
Number:
2647
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Yavuz Havlucu (Manisa, Turkey), Yavuz Havlucu, Fikret Kurhan, Timur Pirildar, Tugba Goktalay, Aysin Sakar Coskun, Pinar Celik, Arzu Yorgancioglu. Pulmonary infections in patients receiving treatment of tumor necrosis factor alpha antagonists. Eur Respir J 2015; 46: Suppl. 59, 2647
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test?
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Latent tuberculosis screening and entering antibody therapy monoclonares against tumor necrosis factor
Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers
Year: 2016
Miliary tuberculosis during treatment with anti TNF alpha - a report of four cases
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II
Year: 2013
Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy
Source: Annual Congress 2011 - Clinical challenges in tuberculosis
Year: 2011
Tuberculosis in patients receiving treatment of TNF-alpha inhibitors
Source: International Congress 2015 – Case series and clinical conundrums in TB
Year: 2015
Anti-TNF-alpha therapy in patients with latent tuberculosis incidence
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Diagnosing latent tuberculosis in immunocompromised patients measuring blood IP-10 production capacity: An analysis of chronic renal faulire patients
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Necrosis as a predictor of infection in granulomatous lung disease
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013
Initiation of anti-TNF therapy within 3 weeks of LTBI treatment in patients with immune-mediated inflammatory diseases
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014
Screening for latent tuberculosis before tumour necrosis factor antagonist therapy
Source: Eur Respir J 2015; 45: 1510-1512
Year: 2015
Screening for latent tuberculosis before tumour necrosis factor antagonist therapy
Source: Eur Respir J 2015; 45: 1512-1513
Year: 2015
TB in the immunocompromised host
Source: Eur Respir Mon 2012; 58: 230-241
Year: 2012
Opportunistic infections in patients with lung tuberculosis
Source: International Congress 2015 – Case series and clinical conundrums in TB
Year: 2015
Inhaled IFN-γ for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-γ deficiency
Source: Eur Respir J 2004; 24: 367-370
Year: 2004
Clinical characteristics of pulmonary nocardiosis in immunocompetent patients
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015
Biomarkers of systemic inflammatory response in patients with tuberculosis, combined with HIV infection
Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers
Year: 2016
Treatment for latent tuberculosis infection in migrants carries a low risk of hepatotoxicity
Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention
Year: 2014
Multiplexed cytokine and chemokine profiling in patients with latent tuberculosis infection: Treatment effect
Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention
Year: 2014
Expression levels of membrane-bound tumor necrosis factor alpha receptors in active tuberculosis and healthy individuals
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept